Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24‐Week, Phase III Study
Samuel A. Kocoshis,Russell J. Merritt,Susan Hill,Susan Protheroe,Beth A. Carter,Simon Horslen,Simin Hu,Stuart S. Kaufman,David F. Mercer,Mikko P. Pakarinen,Robert S. Venick,Paul W. Wales,Andrew A. Grimm
DOI: https://doi.org/10.1002/jpen.1690
2019-09-08
Journal of Parenteral and Enteral Nutrition
Abstract:<article><section class="article-section article-section__abstract"><h3 class="article-section__sub-title section1"> Background</h3><p>This study evaluated the safety and efficacy of teduglutide in pediatric patients with short bowel syndrome–associated intestinal failure (SBS‐IF).</p><h3 class="article-section__sub-title section1"> Methods</h3><p>A 24‐week, phase III trial with 2 randomized, double‐blind teduglutide dose groups and a nonblinded standard of care (SOC) arm was used; patients received 0.025 mg/kg or 0.05 mg/kg teduglutide once daily. Safety end points included treatment‐emergent adverse events (TEAEs) and growth parameters. The primary efficacy/pharmacodynamic end point was the number of patients who achieved a ≥20% reduction in parenteral support (PS) from baseline at week 24.</p><h3 class="article-section__sub-title section1"> Results</h3><p>All 59 enrolled patients completed the study (0.025 mg/kg, n = 24; 0.05 mg/kg, n = 26; SOC, n = 9). Baseline demographics and disease characteristics were comparable among groups. TEAEs were reported by 98% and 100% of patients in the teduglutide and SOC groups, respectively. The most common TEAEs in the teduglutide‐treated groups were pyrexia and vomiting. The primary end point was achieved by 13 (54.2%), 18 (69.2%), and 1 (11.1%) patients who received 0.025 mg/kg teduglutide, 0.05 mg/kg teduglutide, and SOC, respectively (<i>P</i> < 0.05 vs SOC). Both 0.025‐mg/kg and 0.05‐mg/kg teduglutide groups showed clinically significant reductions in PS volume (<i>P</i> < 0.05 vs SOC), PS calories, days per week and hours per day of PS infusions, and increases in enteral nutrition and plasma citrulline at week 24 compared with baseline. Two (8.3%, 0.025 mg/kg teduglutide) and 3 patients (11.5%, 0.05 mg/kg teduglutide) achieved enteral autonomy. </p><h3 class="article-section__sub-title section1"> Conclusion</h3><p>The safety profile of teduglutide was similar to that reported previously in children and adults. Treatment with teduglutide was associated with significant reductions in PS for pediatric patients with SBS‐IF over 24 weeks.</p></section><section class="article-section article-section__full"><h2 class="article-section__title section__title section1"> Clinical Relevancy Statement</h2><p>Parenteral support (PS)–dependent children with short bowel syndrome–associated intestinal failure (SBS‐IF) have a high disease burden. In this 24‐week, phase III study of 2 randomized, double‐blind teduglutide dose groups and a nonblinded standard of care group, treatment with teduglutide reduced PS volume, calories, and infusion time in pediatric patients with SBS‐IF. The safety profile was consistent with previous experience in adults and children with SBS‐IF. In conjunction with expert management by intestinal rehabilitation specialists in this study, daily teduglutide injection was well tolerated and promoted intestinal adaptation, as evidenced by reductions of PS requirements in children with SBS‐IF.</p><h2 class="article-section__title section__title section1"> Introduction</h2><p>Short bowel syndrome (SBS) is the most common cause of intestinal failure (IF), defined as gut function inadequate for satisfactory absorption of macronutrients, water, or electrolytes to maintain growth and development.<span><a class="bibLink tab-link" href="#jpen1690-bib-0001">1</a></span> Long‐term administration of parenteral support (PS; parenteral nutrition and/or intravenous fluids) is life‐saving but associated with potentially life‐threatening complications, including IF‐associated liver disease, central line–associated blood stream infections, and central venous thrombosis.<span><a class="bibLink tab-link" href="#jpen1690-bib-0001">1</a>-<a class="bibLink tab-link" href="#jpen1690-bib-0003">3</a></span> Enhancing intestinal adaptation minimizes dependence on PS, thereby reducing the risk of complications<span><a class="bibLink tab-link" href="#jpen1690-bib-0004">4</a>-<a class="bibLink tab-link" href="#jpen1690-bib-0006">6</a></span> and potentially improving quality of life.<span><a class="bibLink tab-link" href="#jpen1690-bib-0007">7</a>, <a class="bibLink tab-link" href="#jpen1690-bib-0008">8</a></span></p><p>Glucagon‐like peptide‐2 (GLP‐2), a hormone secreted by enteroendocrine L cells in the distal ileum and proximal colon in response to the presence of unabsorbed luminal nutrients,<span><a class="bibLink tab-link" href="#jpen1690-bib-0009">9</a>, <a class="bibLink tab-link" href="#jpen1690-bib-0010">10</a></span> is a key component of the adaptive response to intestinal malabsorption.<span><a class="bibLink tab-link" href="#jpen1690-bib-0009">9</a>-<a class="bibLink tab-link" href="#jpen1690-bib-0012">12</a></span> Teduglutide, a recombinant human GLP‐2 analogue, is approved in the United States and Europe for the treatment of patients ≥1 year of age with SBS‐IF at a dose of 0.05 mg/kg <p>-Abstract Truncated-</p>
nutrition & dietetics